RxDoctor Payments DataLook up a doctor →

Gregg Kaiser, MD

Ophthalmology · Greenville, SCNPI 1386627925

Payments from drug & device makers

$387,447in general payments, 2019–2025

Across 116 payments — averaging $3340.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$373K
  • Regeneron$11K
  • US Retina LLC$2K
  • Genentech USA, Inc.$545
  • Regeneron Healthcare Solutions, Inc.$335
  • Apellis Pharmaceuticals, Inc.$259
  • plus $918 from 10 others

What the payments were for

  • Food & beverage$2,05749%
  • Ownership interest$2,12151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$387,447 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,629,700
Medicare patients
1,236
Services billed
37,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$7,443
Prednisolone Acetate152$6,624
CombiganBrimonidine Tartrate/Timolol12$4,526
ProlensaBromfenac Sodium11$3,862
LumiganBimatoprost13$3,102
Latanoprost166$1,225
Timolol Maleate50$956
Difluprednate17$916
ValacyclovirValacyclovir Hcl12$748
Ofloxacin64$690
Brimonidine Tartrate26$566
Ketorolac Tromethamine22$526
ErythromycinErythromycin Base46$514
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$491
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha16$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$89$15,07137 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$138$3,86211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →